Cargando…
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help...
Autores principales: | Kochhar, Sonali, Kim, Denny, Excler, Jean-Louis, Condit, Richard C., Robertson, James S., Drew, Stephen, Whelan, Mike, Wood, David, Fast, Patricia E., Gurwith, Marc, Klug, Bettina, Khuri-Bulos, Najwa, Smith, Emily R., Chen, Robert T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343648/ https://www.ncbi.nlm.nih.gov/pubmed/32653276 http://dx.doi.org/10.1016/j.vaccine.2020.06.044 |
Ejemplares similares
-
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines
por: Kochhar, Sonali, et al.
Publicado: (2020) -
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines
por: Gurwith, Marc, et al.
Publicado: (2020) -
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
por: Condit, Richard C, et al.
Publicado: (2020) -
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines
por: Kim, Denny, et al.
Publicado: (2020) -
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus
por: Hernandez, Libia Milena, et al.
Publicado: (2022)